Core Laboratories Inc. 8-K Summary
Business context and reporting period
Core Laboratories Inc. filed this Form 8-K on June 30, 2023, reporting matters voted on at its Annual Meeting of Shareholders held June 28, 2023, in Houston, Texas. The filing is not a periodic financial report and does not provide current-period operating or financial results.
Key financial metrics and capital structure
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics. It states that KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Material changes versus the prior comparable period
No comparable-period financial information or material operating changes are reported. The principal governance change is the extension of the 2014 Non-Employee Director Stock Incentive Plan through June 28, 2033.
Shareholder votes, outlook, and unusual items
- Both Class I director nominees, Harvey Klingensmith and Curtis Anastasio, were elected.
- KPMG’s appointment was ratified by 40,549,322 votes for, 910,252 against, and 62,515 abstentions.
- Executive compensation was approved on an advisory basis by 36,172,862 votes for, 1,265,529 against, and 803,147 abstentions.
- Shareholders selected annual voting on executive compensation, with 35,944,561 votes for a one-year frequency, compared with 10,314 for two years and 2,247,398 for three years.
- The Board decided to include an annual executive-compensation vote in future proxy materials. The Company does not currently plan to submit another frequency proposal in its 2024 proxy materials, but plans to seek advisory approval of named executive officer compensation.
- The amended and restated Director Plan was approved by 36,300,313 votes for, 1,801,924 against, and 139,301 abstentions.
Important facts for investors to verify
- Verify the final certified voting results and the elected directors in the Company’s subsequent proxy and governance disclosures.
- Review the amended Director Plan for changes beyond the stated term extension, including share limits, eligibility, and award terms.
- Confirm future proxy materials reflect annual say-on-pay voting and assess subsequent shareholder approval results.
- Consult the Company’s periodic filings for financial performance, debt, liquidity, risks, contingencies, and management outlook, none of which are provided in this 8-K.